TODAY'S HEADLINES

New diabetes drug competes against leading brands

FDA approved lixisenatide (Adlyxin), a once-daily injection for type 2 diabetes, which will compete against the once-weekly pen dulaglutide (Trulicity) and the injectable liraglutide (Victoza). Read more

FDA: Antibiotics class must carry warning

FDA added new safety labeling on fluoroquinolones (Levaquin, Cipro and other branded drugs), to enhance warnings about their association with disabling and potentially permanent side effects. Read more

CONTINUING PHARMACY EDUCATION

Expanding vaccination rates through pharmacist-initiated patient identification and assessment

This month's CE activity, "Expanding vaccination rates through pharmacist-initiated patient identification and assessment," is open for pharmacists and pharmacy technicians.
The goal of this activity is to educate pharmacists and pharmacy technicians about current vaccine recommendations so that they can identify adolescent and adult patients who may need vaccinations. Readers will also gain knowledge about where to obtain information about current vaccine recommendations.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

FDA approves first once-monthly injection to lower cholesterol

FDA recently approved evolocumab (Repatha) Pushtronex system, the first monthly single-dose injection of a PCSK9 inhibitor. Read more

August 03, 2016

Related Articles

Major diabetes drug cuts heart attack risk

Fighting superbugs: 4 recommendations from Consumer Reports